Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Aug 08, 2023
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 Aug 02, 2023
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study Aug 01, 2023
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences Jul 31, 2023
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Jul 31, 2023
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Jul 27, 2023
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma Jul 27, 2023
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol Jul 25, 2023
